受强制性开放获取政策约束的文章 - subba digumarthy了解详情
无法在其他位置公开访问的文章：2 篇
Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia
M Nishino, SK Mathai, D Schoenfeld, SR Digumarthy, RL Kradin
Human Pathology 45 (2), 342-351, 2014
强制性开放获取政策： US National Institutes of Health
Case 18-2009: A 24-Year-Old Woman with AIDS and Tuberculosis with Progressive Cough, Dyspnea, and Wasting
D Wilson, RM Hurtado, S Digumarthy
New England Journal of Medicine 360 (23), 2456-2464, 2009
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：60 篇
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, ...
Science translational medicine 3 (75), 75ra26-75ra26, 2011
强制性开放获取政策： US National Institutes of Health
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247-4253, 2009
强制性开放获取政策： US National Institutes of Health
Detection of mutations in EGFR in circulating lung-cancer cells
S Maheswaran, LV Sequist, S Nagrath, L Ulkus, B Brannigan, CV Collura, ...
New England Journal of Medicine 359 (4), 366-377, 2008
强制性开放获取政策： US National Institutes of Health, Howard Hughes Medical Institute
EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis
JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ...
Clinical cancer research 22 (18), 4585-4593, 2016
强制性开放获取政策： US National Institutes of Health
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ...
Cancer discovery 6 (10), 1118-1133, 2016
强制性开放获取政策： US National Institutes of Health
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee, JW Neal, ...
Cancer discovery 5 (7), 713-722, 2015
强制性开放获取政策： US National Institutes of Health
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ...
Annals of Oncology 22 (12), 2616-2624, 2011
强制性开放获取政策： US National Institutes of Health
Acquired resistance to crizotinib from a mutation in CD74–ROS1
MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ...
New England Journal of Medicine 368 (25), 2395-2401, 2013
强制性开放获取政策： US National Institutes of Health
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for …
Z Piotrowska, H Isozaki, JK Lennerz, JF Gainor, IT Lennes, VW Zhu, ...
Cancer discovery 8 (12), 1529-1539, 2018
强制性开放获取政策： US National Institutes of Health, LUNGevity Foundation, USA
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
AC Faber, RB Corcoran, H Ebi, LV Sequist, BA Waltman, E Chung, J Incio, ...
Cancer discovery 1 (4), 352-365, 2011
强制性开放获取政策： US National Institutes of Health
Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ...
Journal of Thoracic Oncology 17 (3), 399-410, 2022
强制性开放获取政策： US National Institutes of Health
Combination olaparib and temozolomide in relapsed small-cell lung cancer
AF Farago, BY Yeap, M Stanzione, YP Hung, RS Heist, JP Marcoux, ...
Cancer discovery 9 (10), 1372-1387, 2019
强制性开放获取政策： US National Institutes of Health, Howard Hughes Medical Institute, German …
A phase I study of erlotinib and hydroxychloroquine in advanced non–small-cell lung cancer
SB Goldberg, JG Supko, JW Neal, A Muzikansky, S Digumarthy, P Fidias, ...
Journal of Thoracic Oncology 7 (10), 1602-1608, 2012
强制性开放获取政策： US National Institutes of Health, LUNGevity Foundation, USA
Chemotherapy with erlotinib or chemotherapy alone in advanced non‐small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
SB Goldberg, GR Oxnard, S Digumarthy, A Muzikansky, DM Jackman, ...
The oncologist 18 (11), 1214-1220, 2013
强制性开放获取政策： US National Institutes of Health
MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer
I Dagogo-Jack, S Yoda, JK Lennerz, A Langenbucher, JJ Lin, MM Rooney, ...
Clinical Cancer Research 26 (11), 2535-2545, 2020
强制性开放获取政策： US National Institutes of Health, Lung Cancer Research Foundation, USA
Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA
I Dagogo-Jack, AR Brannon, LA Ferris, CD Campbell, JJ Lin, KR Schultz, ...
JCO precision oncology 2, 1-14, 2018
强制性开放获取政策： US National Institutes of Health
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
JK Sabari, V Velcheti, K Shimizu, MR Strickland, RS Heist, M Singh, ...
Clinical Cancer Research 28 (15), 3318-3328, 2022
强制性开放获取政策： US National Institutes of Health, Damon Runyon Cancer Research Foundation
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression≥ 50%
JF Gainor, H Rizvi, EJ Aguilar, F Skoulidis, BY Yeap, J Naidoo, ...
Annals of Oncology 31 (3), 404-411, 2020
强制性开放获取政策： US National Institutes of Health, Damon Runyon Cancer Research Foundation
出版信息和资助信息由计算机程序自动确定